

GLP-1 Weight Reduction
Semaglutide/Tirzepatide is a revolutionary GLP-1 receptor agonist that was originally developed for patients with Type 2 diabetes, but when physicians noticed how much weight their patients were losing, they began to study Semaglutide/Tirzepatide exclusively for weight loss. Clinic trials demonstrate that up to 90% of participants using Semaglutide/Tirzepatide lost at least 5% of their weight; 50% of participants lost 15%; and 30% of participants lost 20%. There is no other weight loss drug or plan on the market that compares. In June, 2022, the FDA approved Semaglutide for weight loss.
​
How does Semaglutide/Tirzepatide work?
Semaglutide/Tirzepatide acts like GLP-1 (a gut hormone) to:
- Increase insulin production
- Decrease glucagon synthesis
- Delay gastric emptying
- Suppress hunger. It signals your brain that you are full so you can lose weight without feeling like you are depriving yourself of calories.